Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v20-FR Version v6-FR
Language French French
Date Updated 2022-07-08 2022-01-26
Drug Identification Number 02443449 02443449
Brand name MYLAN-NAPROXEN/ESOMEPRAZOLE MR MYLAN-NAPROXEN/ESOMEPRAZOLE MR
Common or Proper name NAPROXEN/ESOMEPRAZOLE MR NAPROXEN/ESOMEPRAZOLE MR
Company Name MYLAN PHARMACEUTICALS ULC MYLAN PHARMACEUTICALS ULC
Ingredients ESOMEPRAZOLE NAPROXEN ESOMEPRAZOLE NAPROXEN
Strength(s) 20MG 500MG 20MG 500MG
Dosage form(s) TABLET (IMMEDIATE AND DELAYED-RELEASE) TABLET (IMMEDIATE AND DELAYED-RELEASE)
Route of administration ORAL ORAL ORAL ORAL
Packaging size 60 BT 60 BT
ATC code M01AE M01AE
ATC description ANTIINFLAMMATORY/ANTIRHEUMATIC PROD.,NON-STEROIDS ANTIINFLAMMATORY/ANTIRHEUMATIC PROD.,NON-STEROIDS
Reason for shortage Shortage of an active ingredient. Shortage of an active ingredient.
Anticipated start date 2022-03-16 2022-02-02
Actual start date 2022-02-18
Estimated end date 2022-06-23 2022-03-29
Actual end date 2022-06-22
Shortage status Resolved Anticipated shortage
Tier 3 Status No No
Company comments
Health Canada comments